MNPR

Rating neutralAI Memo

Monopar Therapeutics

As of 2026-07-19/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-19 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

ALXN1840 NDA submission and regulatory-status update • 2026-10-17

Expected move: +3%

Biggest risk

NDA timing, FDA outcome, clinical translation, launch execution, and future commercialization costs remain unresolved. No verified post-earnings analyst revisions, consensus surprise, or target changes are available.

Invalidation

Break below $75 or thesis failure.

What would change my mind?

ALXN1840 clinical data and a successful NDA submission could create a regulatory and commercial rerating, while the reported cash position provides meaningful development runway.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-07-19

Base target

$115

p=50%

Bull target

$145

p=25%

Bear target

$75

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Potential Wilson disease commercialization path
ALXN1840 clinical data and a successful NDA submission could create a regulatory and commercial rerating, while the reported cash position provides meaningful development runway.
The anchor price is $111.12 versus a displayed median analyst target of $114.75, but target count is unavailable.

BearKey bullets

Commercial launch execution and demand remain unproven.
NDA submission or FDA review could be delayed or unsuccessful.
Peer comparability and analyst coverage are limited.

WatchKey bullets

ALXN1840 NDA submission and regulatory-status update

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $115 (p=50%)

Bull/Bear spread: +30% / -33%

Vs latest close: Bull +30% · Base +3% · Bear -33%

Scenario probabilities

Bull Target: $145 (p=25%)Base Target: $115 (p=50%)Bear Target: $75 (p=25%)

Commentary

Recent-news coverage and social context are unavailable or insufficient, so sentiment scores are treated as neutral/no-signal rather than positive evidence. Post-earnings price reaction and analyst revision data are also unavailable. The primary-source evidence supports a monitoring thesis centered on NDA status, not a high-conviction directional call.

As of 2026-07-19 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

ALXN1840 clinical data and a successful NDA submission could create a regulatory and commercial rerating, while the reported cash position provides meaningful development runway.

Bear Case

Drivers

Scannable catalysts and supporting factors

Potential Wilson disease commercialization path

Scenarios

Bull Target (Scenario probability)

$145 / p=25% prob

Base Target (Scenario probability)

$115 / p=50% prob

Bear Target (Scenario probability)

$75 / p=25% prob

Price $111 as of 2026-07-17

Nearest Scenario: Base (∆ 3%)

Targets vs latest close: Bull +30% · Base +3% · Bear -33%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-10-17
ALXN1840 NDA submission and regulatory-status update
Management said the NDA for ALXN1840 in Wilson disease was on track for mid-2026, with commercial-readiness work underway. Submission status and FDA timing are not confirmed in the packet. [#PR-EARNINGS-2026-05-15] [#SEC-8K-2026-05-14]
Prob 55.00% • Move 15.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Potential Wilson disease commercialization path
2027-07-19
Positive Phase 3 FoCus analyses and reported cash runway through at least December 31, 2027 support continued regulatory and potential commercial activity, but approval, launch execution, and adoption remain uncertain. [#PR-EARNINGS-2026-05-15]
Prob 35% • Move 30% • Priced-in 30%

Risks

Commercial launch execution and demand remain unproven.
NDA submission or FDA review could be delayed or unsuccessful.
Peer comparability and analyst coverage are limited.
Phase 3 results may not translate into approval, labeling, or commercial uptake.
R&D spending increased year over year, and continued development may increase cash burn.

Peers

Symbol	Summary
CADL	Same-sector, similar-market-cap candidate, but direct indication and program comparability are not established in the packet; weak comp.
NGNE	Same-sector, similar-market-cap candidate; operating and clinical comparability to MNPR is unverified, so peer evidence is limited.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-19

AI Stock Memo: MNPR - Monopar Therapeutics - RankAlpha